Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program Cell Type
Functionality
Target(s) Indication(s) Research PreClin Phase 1 Phase 2 Phase 3
iPSC-derived Cell Products
FT500 iNK
Non-engineered
PD1/PD-L1 Solid tumors + CPI

 Solid Tumor

FT516 iNKhnCD16 + IL15RF
n/a AML

 Hematology

CD20 BCL + CD20 mAb

 

PD-L1 Solid tumors + PD-L1 mAb

 

FT596 iNKhnCD16 + IL15RF + CAR-19 CD19, CD20 BCL, CLL ± CD20 mAb

 

FT538 iNKhnCD16 + IL15RF + CD38-KO
n/a AML

 

CD38 MM + CD38 mAb

 

FT576 iNKhnCD16 + IL15RF + CD38-KO + CAR-BCMA BCMA, CD38 MM ± CD38 mAb

 

FT819 iTCAR-19, TCR-KO CD19 Hematology

 

FT536 iNKhnCD16 + IL15RF + CD38-KO + CAR-MICA/B MICA/B Solid tumors ± mAb

 

FT573 iNKhnCD16 + IL15RF + CD38-KO + CAR-B7H3 B7H3 Solid tumors ± mAb

 

iPSC-derived Cell Products – Cancer Immunotherapy Collaborations
Janssen iNK and iT undisclosed ≤ 4 tumor targets

 

Ono Pharma iT undisclosed ≤ 2 tumor targets

 

Donor-derived Cell Products
ProTmune™ Hematopoietic graftNon-engineered, donor-derived cells n/a Hematology

 

iPSC-DERIVED CELL PRODUCTS

Program Indication Phase
FT500
iNK
Non-engineered
Solid tumors + CPI 1
FT516
iNKhnCD16 + IL15RF
AML 1
BCL + CD20 mAb 1
Solid tumors + PD-L1 mAb 1
FT596
iNK
hnCD16 + IL15RF + CAR-19
BCL, CLL ± CD20 mAb 1
FT538
iNK
hnCD16 + IL15RF + CD38-KO
AML 1
MM + CD38 mAb 1
FT576
iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
MM ± CD38 mAb Pre
FT819
iT
CAR-19, TCR-KO
Hematology Pre
FT536
iNK
hnCD16 + IL15RF + CD38-KO + CAR-MICA/B
Solid tumors ± mAb
Pre
FT573
iNK
iNK/ hnCD16 + IL15RF + CD38-KO + CAR-B7H3
Solid tumors ± mAb
Pre

iPSC-DERIVED CELL PRODUCTS – CANCER IMMUNOTHERAPY COLLABORATIONS

Program Indication Phase
Janssen
iNK and iT
≤ 4 tumor targets Research
Ono Pharma
iT
≤ 2 tumor targets Research

DONOR-DERIVED CELL PRODUCTS

Program Indication Phase
ProTmune™
Hematopoietic graft
Non-engineered, donor-derived cells
Hematology 2

iPSC = induced pluripotent stem cell iNK = iPSC-derived NK Cell iT = iPSC-derived T cell mAb = monoclonal antibody CPI = checkpoint inhibitor hnCD16 = high affinity, non-cleavable CD16 Fc receptor IL15-RF = IL15 receptor fusion CD38-KO = CD38 knock-out CAR = chimeric antigen receptor TCR-KO = T-cell receptor knock-out AML = acute myelogenous leukemia BCL = B-cell lymphoma CLL = chronic lymphocytic leukemia  MM = Multiple myeloma